Clinical data show superior immunogenicity in the elderly, comparable to that seen in younger adults
[by Ji, Yong Jun] 바카라 꽁 머니 Korea announced on August 5 its active participation in protecting high-risk populations aged 65 and older in Korea through the 2025-2026 National Immunization Program (NIP).
This announcement follows the recent procurement by the Korea Disease Control and Prevention Agency (KDCA) of 2,019,000 doses of 바카라 꽁 머니's COVID-19 vaccine as part of the current season's supply tender. 바카라 꽁 머니 expressed its intention to promptly deliver the vaccine in alignment with the government's immunization plan and to contribute to safeguarding the health of high-risk populations, particularly the elderly.
"COVID-19 continues to pose a significant threat due to its high transmissibility and elevated risk of severe illness among those aged 65 and older. We are committed to supporting the protection of high-risk populations in alignment with the government's vaccination schedule," stated Juno Sangpyo Kim, General Manager of Moderna Korea.
Moderna's COVID-19 vaccine has demonstrated its efficacy and safety, as evidenced by large-scale Phase 3 clinical trials and extensive Real-World Evidence (RWE) data. Notably, the vaccine has proven immunogenic responses in individuals aged 65 and older that were comparable to those observed in younger populations. Its strong immunogenicity and favorable safety profile, regardless of prior vaccination history, underscore the vaccine’s clinical value.
Since the early stages of the COVID-19 pandemic, approximately 29.18 million doses of the 바카라 꽁 머니 vaccine have been administered in Korea, generating a substantial body of data supporting its efficacy and safety. According to a study conducted by the KDCA, the 바카라 꽁 머니 vaccine exhibited the lowest rate of breakthrough infections among the vaccines administered in Korea during the initial phase of the pandemic.
Since 2021, 바카라 꽁 머니 has remained the sole company manufacturing messenger ribonucleic acid (mRNA) COVID-19 vaccines in Korea, in partnership with Samsung Biologics. In addition to vaccine production, the company has undertaken various initiatives to strengthen Korea's mRNA technology capabilities, including joint research with the National Institute of Infectious Diseases (NIID), under the KDCA, on a vaccine candidate targeting severe fever with thrombocytopenia syndrome (SFTS), as well as collaborations with the K-NIBRT of KAIST and Yonsei University aimed at cultivating mRNA research talent.